NU664C Study Guide for Midterm Exam Already Verified A+

NU664C Study Guide for Midterm Exam Already Verified A+ Know the route of administration for newer agent asenapine (Saphris) and what instructions should be given to the patient regarding administration. Route- Sublingual Not to eat or drink for 10 minutes after medication administration Not to swallow or chew the capsule. Asenapine is an atypical antipsychotic (serotonin-dopamine antagonist, as a mood stabilizer). Asenapine is not absorbed after swallowing (less than 2% bioavailable orally) and thus must be administered sublingually (35% bioavailable), as swallowing would render asenapine inactive. Patients should be instructed to place the tablet under the tongue and allow it to dissolve completely, which will occur in seconds; tablet should not be divided, crushed, chewed, or swallowed. Patients may not eat or drink for 10 minutes following sublingual administration so that the drug in the oral cavity can be absorbed locally and not washed into the stomach (where it would not be absorbed). Due to rapid onset of action, can be used as a rapid acting "prn" or "as needed" dose for agitation or transient worsening of psychosis or mania instead of an injection. Treatment should be suspended if absolute neutrophil count falls below 1,000/mm3. Know and describe the top atypical antipsychotic with greatest incidence of prolonged QTc interval. Ziprasidone (Geodon). Normal QTc =450. 470, Call Cardiologist 500, stop all meds. Ziprasidone (Geodon) has been associated with a dose-related prolongation of the QTc QTc interval prolongation is greatest with ziprasidone and least with olanzapine. Ziprasidone (Geodon) an atypical antipsychotic (serotonin-dopamine antagonist; second-generation antipsychotic; also a mood stabilizer. Ziprasidone is prescribed for Schizophrenia, delaying relapse in schizophrenia, acute agitation in schizophrenia (intramuscular), acute mania/mixed mania, bipolar maintenance, other psychotic d/o, bipolar depression, behavioral disturbances in dementias, behavioral disturbances in children and adolescents, and disorders associated with problems with impulse control. Ziprasidone blocks dopamine 2 receptors, reducing positive symptoms of psychosis and stabilizing affective symptoms. Blocks serotonin 2A receptors, causing enhancement of dopamine release in certain brain regions and thus reducing motor side effects and possible improving cognitive